SPONSORSHIP

The SPECTA platform is supported by Alliance Healthcare, a member of the AmerisourceBergen group.
WHAT IS SPECTA?

SPECTA is the translational research infrastructure of the EORTC.

The goal of SPECTA is to enable translational research projects to broaden our knowledge on cancer, build scientific hypothesis for future clinical trials, and promote international collaborations.

Some SPECTA projects will organise Multidisciplinary Tumor Boards (MTB) to report clinically actionable molecular alterations to clinicians.

SPECTA is based on:

- A protocol that is reviewed and approved Ethics Committees throughout Europe, describing SPECTA infrastructure.
- A patient informed consent form to collect samples, images, questionnaires and clinical data for cancer research.
- A quality-controlled workflow for the collection of clinical data and human biological material. SPECTA relies on a centralised biobank and more that 15 specialized laboratories, performing the most recent molecular and cellular analysis.
- A pan-European network of 250 clinicians in 188 different centers and 22 European countries, to reach patient broadly, allowing recruitment of around 800 patients per year.
- A quality-controlled workflow for the collection of clinical data and human biological material. SPECTA relies on a centralised biobank and more that 15 specialized laboratories, performing the most recent molecular and cellular analysis.
- A patient informed consent form to collect samples, images, questionnaires and clinical data for cancer research.
- A quality-controlled workflow for the collection of clinical data and human biological material. SPECTA relies on a centralised biobank and more that 15 specialized laboratories, performing the most recent molecular and cellular analysis.
- A pan-European network of 250 clinicians in 188 different centers and 22 European countries, to reach patient broadly, allowing recruitment of around 800 patients per year.

PAST PROJECTS:

- SPECTAcolor recruited 835 evaluable patients with a diagnosis of metastatic colorectal cancer. A NGS panel was performed on 584 patients and gene expression analysis on 124. The SPECTAcolor biobank contains around 800 FFPE samples.
- SPECTAlung collected and analysed (NGS panel) samples and clinical data for 528 patients with diagnosis of pleural, lung, or thymic malignancies.
- AYA a pilot project focuses on the clinical and molecular landscape of adolescent with sarcoma (n=48) or high grade glioma (n=50), aged from 12 to 29, using central pathology review and molecular analysis (WES, RNAseq and methylation array).

PAST & FUTURE PROJECTS

PROJECTS IN THE PIPELINE:

- RP 2148-Measurable Residual Disease (MRD) Pan-tumor longitudinal assessment of MRD in the blood of patients, in the adjuvant settings
- RP2030 ELDORADO To understand the molecular determinant of early oral head and neck cancers.

If you would like to request samples or data, in the scope of a collaboration scan the code here:
CURRENT PROJECTS

SPECTA is EORTC pan-European translational research platform, created to promote development of TR projects in Europe, mainly focusing on the biological aspects of cancer, including molecular profiling and personalized therapy.

SCIENTIFIC PUBLICATIONS

For more information on our latest publications, please scan our QR codes below:

- [SPECTAlung](#)  [AYA](#)  [IMMUcan](#)
- [Arcagen (i)](#)  [Arcagen (ii)](#)

**IMMUcan**

IMMUcan is a project funded by the Innovative Medicines Initiative. Its goal is to better understand the tumor microenvironment.

Sample and clinical data from 3,000 patients with lung, head and neck, colorectal, breast, and renal cancer will be collected and analysed (WES, RNAseq, miF and Imaging Mass Cytometry).

A report with the conclusion of the molecular analysis will be shared with the local investigator within 6 weeks after patient enrollment, and discussed during MTB.

**Arcagen**

The project is a collaboration with EURACAN. The goal is to broaden our clinical and molecular understanding of rare cancers in Europe. 1,000 patients with rare cancers will be analysed using a FMI NGS panel to generate a clinically-annotated molecular database.

A report with conclusion of the molecular analysis will be shared with the local investigator within 4 weeks after patient enrollment and discussed during MTB.

Arcagen is funded by F. Hoffman-La Roche.

**Bioranot**

This project focuses on understanding the impact of radon exposure in the development of lung cancers, especially the ones presenting driver molecular alterations. Radon exposure (acute using detector and cumulative with a questionnaire) will be measured and correlated to patient diagnosis.

The project is funded via grants from the Euratom research and training program (Radonorm), Novartis, Ely Lilly, Beigene, Aureus Ars & Scientia and the EORTC Lung Cancer Group.
CONTACT INFORMATION

For more information or if you want to enrol patients in SPECTA: